01682nas a2200325   4500000000100000008004100001260001300042653001500055653001000070653001200080653003000092653001100122653001100133653002400144653002500168653000900193653001600202653002400218653001300242653002200255100001200277700001400289700001900303700001400322245008800336300001000424490000700434520090100441022001401342       1994                            d  c1994 Oct10aAdolescent10aAdult10aDapsone10aDrug Therapy, Combination10aFemale10aHumans10aLeprosy, Borderline10aLeprosy, Tuberculoid10aMale10aMiddle Aged10aProspective Studies10aRifampin10aTreatment Outcome1 aKar P K1 aArora P N1 aRamasastry C V1 aDhaka R S00aA clinicopathological study of multidrug therapy in borderline tuberculoid leprosy.  a336-70 v923 a<p>A study was undertaken to evaluate the efficacy of multidrug therapy as per WHO recommendation in 50 fresh cases (46 males and 4 females) suffering from borderline tuberculoid leprosy. All were given multidrug therapy consisting of rifampicin 600 mg once a month and dapsone 100 mg daily for 6 months. At the end of 6 months all were evaluated clinically and histopathological examinations of the lesions were studied. The lesions were still active in 60% of patients clinically; 32% cases receiving multidrug therapy had shown marked improvement. Histologically lymphocytic infiltration in skin still persisted in all the slides examined and nerve infiltration was still present in 68% of cases at the end of 6 months after receiving multidrug therapy. The study shows that treatment with multidrug regimen for 6 months may not be sufficient to treat borderline tuberculoid leprosy cases.</p>  a0019-5847